Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
7.27
-0.31 (-4.09%)
Dec 3, 2024, 2:07 PM EST - Market open
Recursion Pharmaceuticals Employees
Recursion Pharmaceuticals had 500 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
500
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$130,368
Profits / Employee
-$755,502
Market Cap
2.08B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 500 | 0 | - |
Dec 31, 2022 | 500 | 100 | 25.00% |
Dec 31, 2021 | 400 | 69 | 20.85% |
Dec 31, 2020 | 331 | 131 | 65.50% |
Dec 31, 2019 | 200 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Teladoc Health | 5,600 |
Omnicell | 3,650 |
Azenta | 3,500 |
Tandem Diabetes Care | 2,400 |
Astrana Health | 1,800 |
GeneDx Holdings | 1,000 |
Supernus Pharmaceuticals | 652 |
Harmony Biosciences Holdings | 246 |
RXRX News
- 13 days ago - Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery - GlobeNewsWire
- 20 days ago - Recursion and Exscientia Shareholders Approve the Proposed Combination - GlobeNewsWire
- 20 days ago - Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden - GlobeNewsWire
- 4 weeks ago - Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th - GlobeNewsWire
- 6 weeks ago - Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection - GlobeNewsWire
- 2 months ago - Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma - Seeking Alpha
- 2 months ago - Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment - CNBC
- 2 months ago - Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma - GlobeNewsWire